Landau, Heather

selected publications

Prognostic Factors for Postrelapse Survival after ex Vivo CD34⁺-Selected (T Cell-Depleted) Allogeneic Hematopoietic Cell Transplantation in Multiple Myeloma. Biology of blood and marrow transplantation : journal of the American Society for Blood and Marrow Transplantation. 2020 Academic Article GET IT
Accelerated single cell seeding in relapsed multiple myeloma. Nature communications. 2020 Academic Article GET IT
Times cited: 42
Stem Cell Mobilization and Autograft Minimal Residual Disease Negativity with Novel Induction Regimens in Multiple Myeloma. Biology of blood and marrow transplantation : journal of the American Society for Blood and Marrow Transplantation. 2020 Academic Article GET IT
Times cited: 9
Pilot Study of Telehealth Evaluations in Patients Undergoing Hematopoietic Cell Transplantation. Biology of blood and marrow transplantation : journal of the American Society for Blood and Marrow Transplantation. 2020 Academic Article GET IT
Times cited: 15
Off-the-shelf EBV-specific T cell immunotherapy for rituximab-refractory EBV-associated lymphoma following transplantation. The Journal of clinical investigation. 2020 Academic Article GET IT
Times cited: 176
A phase II clinical trial of lenalidomide intensification in patients with serologic/asymptomatic progression of multiple myeloma while on lenalidomide maintenance: a tri-state transplant consortium study. Leukemia & lymphoma. 2020 Article GET IT
Kidney transplantation in AL Amyloidosis: is it time to maximize access?. British journal of haematology. 2019 Article GET IT
Times cited: 7
Presalvage International Staging System Stage and Other Important Outcome Associations in CD34⁺-Selected Allogeneic Hematopoietic Stem Cell Transplantation for Multiple Myeloma. Biology of blood and marrow transplantation : journal of the American Society for Blood and Marrow Transplantation. 2019 Academic Article GET IT
Times cited: 9
Predictive biomarkers and practical considerations in the management of carfilzomib-associated cardiotoxicity. Leukemia & lymphoma. 2018 Letter GET IT
Times cited: 14
Revaccination after Autologous Hematopoietic Stem Cell Transplantation Is Safe and Effective in Patients with Multiple Myeloma Receiving Lenalidomide Maintenance. Biology of blood and marrow transplantation : journal of the American Society for Blood and Marrow Transplantation. 2017 Academic Article GET IT
Times cited: 33
Prognostic and Added Value of Two-Dimensional Global Longitudinal Strain for Prediction of Survival in Patients with Light Chain Amyloidosis Undergoing Autologous Hematopoietic Cell Transplantation. Journal of the American Society of Echocardiography : official publication of the American Society of Echocardiography. 2017 Academic Article GET IT
Times cited: 41
Immunophenotypic evidence for reactive polyclonal marrow plasmacytosis in multiple myeloma patients receiving lenalidomide maintenance. Leukemia & lymphoma. 2017 Article GET IT
Times cited: 1
Gain of chromosome 1q portends worse prognosis in multiple myeloma despite novel agent-based induction regimens and autologous transplantation. Leukemia & lymphoma. 2017 Academic Article GET IT
Times cited: 53
Proteomic profiling in plasma cell disorders: a feasibility study. Leukemia & lymphoma. 2016 Article GET IT
Times cited: 7
Organ response in patients with AL amyloidosis treated with NEOD001, an amyloid-directed monoclonal antibody. American journal of hematology. 2016 Article GET IT
Times cited: 24
Upfront use of plerixafor and granulocyte-colony stimulating factor (GCSF) for stem cell mobilization in patients with multiple myeloma: efficacy and analysis of risk factors associated with poor stem cell collection efficiency. Leukemia & lymphoma. 2016 Academic Article GET IT
Times cited: 12
Treatment of multiple myeloma with monoclonal antibodies and the dilemma of false positive M-spikes in peripheral blood. Clinical biochemistry. 2016 Academic Article GET IT
Times cited: 56
Long-term event-free and overall survival after risk-adapted melphalan and SCT for systemic light chain amyloidosis. Leukemia. 2016 Academic Article GET IT
Times cited: 50
Phase IB study of cabozantinib in patients with relapsed and/or refractory multiple myeloma. Blood. 2016 Article GET IT
Times cited: 14
First-in-Human Phase I/II Study of NEOD001 in Patients With Light Chain Amyloidosis and Persistent Organ Dysfunction. Journal of clinical oncology : official journal of the American Society of Clinical Oncology. 2016 Academic Article GET IT
Times cited: 176
Fractionated stem cell infusions for patients with plasma cell myeloma undergoing autologous hematopoietic cell transplantation. Leukemia & lymphoma. 2016 Academic Article GET IT
Times cited: 5
Upfront plerixafor plus G-CSF versus cyclophosphamide plus G-CSF for stem cell mobilization in multiple myeloma: efficacy and cost analysis study. Bone marrow transplantation. 2016 Academic Article GET IT
Times cited: 47
Light Chain Amyloidosis: Patient Experience Survey from the Amyloidosis Research Consortium. Advances in therapy. 2015 Academic Article GET IT
Times cited: 190
Improved Outcomes After Autologous Hematopoietic Cell Transplantation for Light Chain Amyloidosis: A Center for International Blood and Marrow Transplant Research Study. Journal of clinical oncology : official journal of the American Society of Clinical Oncology. 2015 Academic Article GET IT
Times cited: 172
CD34-Selected Allogeneic Hematopoietic Stem Cell Transplantation for Patients with Relapsed, High-Risk Multiple Myeloma. Biology of blood and marrow transplantation : journal of the American Society for Blood and Marrow Transplantation. 2015 Academic Article GET IT
Times cited: 23
Contribution of chemotherapy mobilization to disease control in multiple myeloma treated with autologous hematopoietic cell transplantation. Bone marrow transplantation. 2015 Academic Article GET IT
Times cited: 32
Second autologous stem cell transplant: an effective therapy for relapsed multiple myeloma. Biology of blood and marrow transplantation : journal of the American Society for Blood and Marrow Transplantation. 2014 Academic Article GET IT
Times cited: 21
Treatment of transplant-eligible patients with multiple myeloma in 2014. Hematology/oncology clinics of North America. 2014 Information Resource GET IT
Times cited: 4
Older patients with myeloma derive similar benefit from autologous transplantation. Biology of blood and marrow transplantation : journal of the American Society for Blood and Marrow Transplantation. 2014 Academic Article GET IT
Times cited: 68
A phase 2 single-center study of carfilzomib 56 mg/m2 with or without low-dose dexamethasone in relapsed multiple myeloma. Blood. 2014 Academic Article GET IT
Times cited: 70
Polyclonal immune activation and marrow plasmacytosis in multiple myeloma patients receiving long-term lenalidomide therapy: incidence and prognostic significance. Leukemia. 2013 Article GET IT
Times cited: 11
Factors impacting stem cell mobilization failure rate and efficiency in multiple myeloma in the era of novel therapies: experience at Memorial Sloan Kettering Cancer Center. Bone marrow transplantation. 2013 Academic Article GET IT
Times cited: 27
Salvage second hematopoietic cell transplantation in myeloma. Biology of blood and marrow transplantation : journal of the American Society for Blood and Marrow Transplantation. 2013 Academic Article GET IT
Times cited: 97
Light-chain amyloidosis: SCT, novel agents and beyond. Bone marrow transplantation. 2012 Information Resource GET IT
Times cited: 9
Bortezomib and dexamethasone consolidation following risk-adapted melphalan and stem cell transplantation for patients with newly diagnosed light-chain amyloidosis. Leukemia. 2012 Academic Article GET IT
Times cited: 74
Cancer-testis antigen expression and immunogenicity in AL amyloidosis. Blood cancer journal. 2012 Academic Article GET IT
Times cited: 9
Patterns of relapse and progression in multiple myeloma patients after auto-SCT: implications for patients' monitoring after transplantation. Bone marrow transplantation. 2012 Academic Article GET IT
Times cited: 44
Clinical and echocardiographic correlates of elevated troponin in amyloid light-chain cardiac amyloidosis. The American journal of cardiology. 2012 Academic Article GET IT
Times cited: 15
The checkpoint kinase inhibitor AZD7762 potentiates chemotherapy-induced apoptosis of p53-mutated multiple myeloma cells. Molecular cancer therapeutics. 2012 Academic Article GET IT
Times cited: 44
Lenalidomide after stem-cell transplantation for multiple myeloma. The New England journal of medicine. 2012 Academic Article GET IT
Times cited: 994
Consensus guidelines for the conduct and reporting of clinical trials in systemic light-chain amyloidosis. Leukemia. 2012 Information Resource GET IT
Times cited: 223
Clonal plasma cell pathophysiology and clinical features of disease are linked to clonal plasma cell expression of cyclin D1 in systemic light-chain amyloidosis. Clinical lymphoma, myeloma & leukemia. 2011 Academic Article GET IT
Times cited: 24
Light chain (AL) amyloidosis: update on diagnosis and management. Journal of hematology & oncology. 2011 Information Resource GET IT
Times cited: 66
Bortezomib, liposomal doxorubicin and dexamethasone followed by thalidomide and dexamethasone is an effective treatment for patients with newly diagnosed multiple myeloma with Internatinal Staging System stage II or III, or extramedullary disease. Leukemia & lymphoma. 2011 Academic Article GET IT
Times cited: 11
Consolidation with bortezomib and dexamethasone following risk-adapted melphalan and stem cell transplant in systemic AL amyloidosis. Amyloid : the international journal of experimental and clinical investigation : the official journal of the International Society of Amyloidosis. 2011 Academic Article GET IT
Times cited: 18
Osteomalacia due to adult Fanconi syndrome in multiple myeloma. Leukemia & lymphoma. 2011 Article GET IT
Times cited: 2
Predictors of survival in patients with systemic light-chain amyloidosis and cardiac involvement initially ineligible for stem cell transplantation and treated with oral melphalan and dexamethasone. British journal of haematology. 2008 Academic Article GET IT
Times cited: 100
The farnesyl transferase inhibitor, tipifarnib, is a potent inhibitor of the MDR1 gene product, P-glycoprotein, and demonstrates significant cytotoxic synergism against human leukemia cell lines. Leukemia. 2007 Academic Article GET IT
Times cited: 31
Clinical manifestations and treatment of newly diagnosed acute lymphoblastic leukemia in adults. Current hematologic malignancy reports. 2006 Information Resource GET IT
Times cited: 12

VIVO Weill Cornell Medical College

Heather Landau Associate Professor of Clinical Medicine

Publications

selected publications

Contact

full name

Phone

Publications

selected publications

Contact

full name